| Company/Division name | POINT Biopharma Inc. |
| Type of work | Manufacturing |
| Reshoring category: | Foreign Direct Investment |
| Total number of jobs (added or to be added): | 100 |
| Year reshoring announced: | 2020 |
| Year reshoring implemented or to be implemented: | 2021 |
| Domestically, the work will be done: | In-house |
| Capital investment ($): | 25 |
| Country(ies) from which reshored: | Canada |
| City reshored to: | Indianapolis |
| State(s) reshored to: | IN |
| If relevant, work nearshored to: | - |
| Industry(ies): | Chemicals |
| Product(s) reshored | radioligands cancer treatments, biopharma |
| What domestic positive factors made reshoring more attractive? | Impact on domestic economy, Lead time/Time to market |
